Rush Ryan Bradford - 17 Dec 2024 SCHEDULE 13G Report for Adverum Biotechnologies, Inc. UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (ADVM)

Filing Manager
Rush Ryan Bradford
Reporting Manager
Rush Ryan Bradford
Security
Adverum Biotechnologies, Inc. UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934
Symbol
ADVM
Shares outstanding
20,588,235 shares
Disclosed Ownership
1,050,000 shares
Ownership
5.1%
Form type
SCHEDULE 13G
Filing time
17 Dec 2024, 17:11:11 UTC
Date of event
17 Dec 2024
SEC
View on sec.gov

Key filing fact

Rush Ryan Bradford disclosed 5.1% ownership in Adverum Biotechnologies, Inc. UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (ADVM) on 17 Dec 2024.

Key facts

  • Rush Ryan Bradford filed SCHEDULE 13G for Adverum Biotechnologies, Inc. UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (ADVM).
  • Disclosed ownership: 5.1%.
  • Date of event: 17 Dec 2024.

Change

  • No earlier schedule filing is available for direct comparison.
  • Current filing was accepted on 17 Dec 2024, 17:11.

Research use

  • This page explains what this Schedule 13D/13G filing tells you before manager-level rows.
  • You can verify ownership claims directly against the original SEC filing.

Evidence

Backed by Schedule 13D/13G

Beneficial ownership values are sourced from the original SEC Schedule 13D/13G filing.

See Original Filing

Reporting persons

Reporting managers (1)

Names, ownership, voting power, signatures, titles, and CIKs as disclosed in this Schedule 13D/G filing.

Name Ownership Shares Owned sole voting power shared voting power Signature Title CIK
Rush Ryan Bradford 5.1% 1,050,000 1,050,000 1,050,000 Rush Ryan Bradford Individual
We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. Here you can make detailed settings or revoke your consent (in part if necessary) with effect for the future. For further information, please refer to our Privacy Policy .